Köln, 07.04.2020

Competent. Agile. Progressive.

The 'convalescent plasma' therapy is not pioneering work - luckily, because the method is one of the most promising approaches to treating Covid-19. Up to now, there is no approved causal therapy for the disease caused by the novel coronavirus Sars-CoV-2.

"We hope that we can help some patients. With other coronaviruses, we know that the procedure works", says Dr. Tim Kümmerle in a live interview. Indeed, international success has been achieved with the method. Studies are currently underway in Germany.

"In this 'mixed' situation, it is difficult to differentiate euphoric popular journalism from well-founded scientific statements. That is why the Advisory Board is so important for our work as a scientific institution", emphasizes Thomas Mosbach, 1st Chairman of the non-profit Initiative, and says: "Speed ​​is important. It is about progressive thinking, competent acting  and making informed decisions."

"In the end, our task is scaling. Fresh plasma transfusions can only be used on a small scale. However, if we succeed in winning immunity donors on a large scale, plasma donation companies can use the antibodies to produce immunoglobulin preparations. The lever is different and we're reaching more patients", adds Erik Tenberken; the pharmacist has become known as the father of pre-exposure prophylaxis against HIV in Germany.

Tenberken and Kümmerle agree: the antibodies have great potential against Covid-19. Even if there are still some uncertainties, the experts assume that immunoglobulin preparations can be an available causal therapy.

In  Univ.-Prof. Dr. med. Oliver Cornely, doctor and researcher at the University Hospital Cologne, the Advisory Board has an internationally renowned researcher in its ranks.

Further candidates for the Advisory Board are waiting for the approval of higher-level institutions for their engagement.